Covidien has announced several leadership changes, which will become effective July 1.
Peter L. Wehrly will become group president, with responsibility for the respiratory & monitoring solutions and vascular therapies businesses, as well as regional responsibility for Japan, Australia, New Zealand and Canada. Wehrly joined Covidien in 2009 as president of respiratory & monitoring solutions.
Michael Sgrignari will become senior vice president, quality and operations, with global responsibility for quality assurance, regulatory affairs, logistics, environmental health & safety and operational excellence. Sgrignari joined Covidien in 1991 and has held positions in manufacturing and operations during his tenure.
Bryan C. Hanson will become group president, with responsibility for the surgical devices and energy-based devices businesses. Hanson joined Covidien in 1992 and has held several positions of increasing responsibility, including his current position, president of energy-based devices.
Hanson, Wehrly and Sgrignari will report to José E. Almeida, currently president of medical devices and CEO-elect. The position of president of medical devices will be eliminated, but Medical Devices will remain an external reporting segment.
James M. Muse, senior vice president of global supply chain, will retire after 32 years of service. Scott Flora, president of surgical devices, who led the business for the past five years, will leave Covidien to pursue other career opportunities.